ABILIFY ASIMTUFII®

Drug Information Related Patent
Hold Company
OTSUKA
Learn More
Dosage and Administration
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Specification
720MG/2.4ML (300MG/ML); 960MG/3.2ML (300MG/ML)
Indication
ABILIFY ASIMTUFII® is used in the treatment of adult schizophrenia for bipolar I disorder in adults maintain monotherapy.
Use
Instructions for Use
API
ARIPIPRAZOLE
API Structure
We Supply
ARIPIPRAZOLE
Note:

In-house Standard/EP/USP
Facility GMP
USMF/CDE/CEP

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
105179512033/4/23
110970072033/4/23
116387572033/4/23
83384272025/3/15
83994692025/6/29
API Patent
Patent NoExpiration Date
83994692025/6/29
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top